In a mouse model of type II diabetes, whereas osteocalcin and osteoprotegerin (osteoblast-specific bone forming markers) were decreased, osteoclast-driven bone resorption markers such as IL-6 and RANK were elevated and coincided with enhanced RANKL and IL-17 expression by CD4+ cells; IL-17 induction was directly promoted upon leptin treatment [74]. Here, IL17A is linked to type 2 diabetes mellitus.